News

Timken's First Quarter 2025 Earnings Report Highlights

Timken's First Quarter 2025 Earnings Report Highlights

Timken Company Reports First Quarter Earnings

The Timken Company (NYSE: TKR), a leader in engineered bearings and industrial motion, has reported its earnings for the first quarter of the fiscal year 2025. The results reflect a sales total of $1.14 billion, marking a decline of 4.2% compared to the same quarter last year. This decrease is attributed to reduced demand within end markets across both segments and currency exchange impacts, although acquisitions offered some mitigation.

In the first quarter, Timken's net income reached $78.3 million, translating to $1.11 per diluted share. This figure falls short of the $103.5 million or $1.46 per diluted share reported during the same period a year prior. The company's net income margin stood at 6.9%, down from 8.7% in the previous year.

Adjusted net income for the quarter, which excludes special items, was $98.6 million, or $1.40 per diluted share, compared to an adjusted net income of $125.7 million, or $1.77 per diluted share in the first quarter of last year. Furthermore, the adjusted EBITDA for the quarter was $208.1 million, accounting for 18.2% of total sales, a decline from $246.4 million or 20.7% from the previous year.

Segment Performance Overview

Engineered Bearings

Sales within the Engineered Bearings sector contributed $760.7 million, reflecting a 5.2% decline compared to the previous year's quarter. The increase in demand from renewable energy sectors was not enough to offset decreased orders from other key markets and adverse currency translations.

Adjusted EBITDA from this segment was $159.2 million, equivalent to 20.9% of sales, down from $181.4 million or 22.6% for the same period last year. This slump in adjusted EBITDA was largely due to lower volumes and a negative mix in pricing impacted by currency fluctuations.

Industrial Motion

The Industrial Motion segment generated sales of $379.6 million, showcasing a minimal decline of 2.1% from the prior year. Higher revenue from the drive systems platform countered some negative trends but was still overshadowed by lesser demand from other platforms and adverse foreign currency translations.

For the quarter, adjusted EBITDA for Industrial Motion came to $67.1 million, or 17.7% of sales, compared to $82.1 million or 21.2% a year ago. The reduction in adjusted EBITDA primarily stemmed from decreased operational volumes and elevated manufacturing costs, though cost-cutting measures contributed positively to the EBITDA margin.

2025 Expectations and Outlook

Timken has revised its outlook for the full fiscal year 2025. The company now anticipates earnings per diluted share in the range of $3.90 to $4.40, coupled with adjusted earnings per diluted share expected between $5.10 and $5.60. These adjustments reflect the estimated net effects of existing tariffs and a prediction for slightly reduced demand for the remainder of the year.

The impact from tariffs alone is expected to strain earnings by approximately $25 million throughout 2025. With continued implementation of mitigation strategies, the company aims to offset these impacts on an annualized basis by year-end.

Additionally, Timken is projecting a decrease in revenue between -2.5% to 0% compared to last year, while reiterating its commitment to achieving operational cost reductions, targeting gross savings of $75 million across the year.

“Our focus is on navigating through this unstable business climate,” shared Richard G. Kyle, the President and CEO. “The team is proactively seeking cost efficiencies while applying pricing strategies to lessen the tariff impact.”

Conference Call and Further Information

The Timken Company will hold a conference call to discuss its financial results during the first quarter at 11 a.m. Eastern Time. Investors and analysts can access presentation materials through the Timken investor relations website before the call.

Frequently Asked Questions

What were Timken's total sales for the first quarter of 2025?

Timken reported first-quarter sales totaling $1.14 billion, reflecting a 4.2% decrease from the previous year.

How did Timken's net income in Q1 2025 compare to Q1 2024?

The net income for Q1 2025 was $78.3 million, down from $103.5 million in Q1 2024.

What is the projected EPS range for Timken in 2025?

The forecast for earnings per diluted share in 2025 is estimated between $3.90 and $4.40.

How did Timken's adjusted EBITDA margins change?

Adjusted EBITDA margins dropped to 18.2% for Q1 2025 from 20.7% the previous year.

Where can investors find more information about Timken's financial results?

Interested investors can access presentation materials for the conference call on the Timken investor relations website.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Aberdeen's Reverse Split: What Investors Need to Know

Updated Category News Views 31

Tackling Aberdeen's New Playbook Aberdeen Multi-Market Income Fund (NYSE: MMT) is pulling the trigger on a 1-for-4 reverse stock split come November 9, 2026. This isn't your average headline-grabbing move but one that could shake up how MMT trades. It’s a classic case of tidying up shop, aiming to bolster the share price and streamline share trading. No Change in Fund...

Continue Reading
Lilly's Sofe-M Shakes Up Ovarian Cancer Treatment

Updated Category News Views 128

Ovarian Cancer Treatment Sees a New Challenger Alright, folks, Eli Lilly (NYSE:LLY) is stepping up with their latest findings in ovarian cancer treatment, and it's got plenty of people in a buzz. They've dropped new data for their investigational drug, Sofetabart mipitecan, or 'Sofe-M' for short, which targets this unrelenting disease with a punch that’s hard to ignore....

Continue Reading
Abbott's Oncodetect Test: Game-Changer for Cancer Recurrence

Updated Category News Views 4

Pioneering Progress in Colorectal Cancer Detection There's a new player in the world of cancer diagnostics, and it's setting a fresh standard. Abbott's Oncodetect test, featured at the ESMO Congress, has shown a profound leap in sensitivity—30 percent over the older whole-exome sequencing approach. For those doing the math on the stock charts, Abbott (NYSE: ABT) is...

Continue Reading
Hansa's Idefirix Shows Promise for Kidney Transplants

Updated Category News Views 22

Compelling Progress from Hansa Biopharma Y'know, navigating through the biotech jungle isn't for the faint-hearted. Hansa Biopharma's recent results with Idefirix could just be the beacon of hope for patients struggling on transplant lists. Announced at the ASN Kidney Week—a name that's got weight, by the way—these findings aren't just filling space. They're promising...

Continue Reading
Unicoin’s 'RISE IN PINK' Blends Crypto and Charity

Updated Category News Views 24

The New Face of Charitable Giving: Crypto and Cause Turning the spotlight on how blockchain and altruism can mesh, Unicoin's latest campaign isn’t just your average philanthropic endeavor. With 'RISE IN PINK', they're out to change the game, blending digital assets with a deep human cause—breast cancer awareness and support. Technology Meets Human Cause Imagine...

Continue Reading
Bimbo Bakeries Teamsters Avert Strike in Chicago

Updated Category News Views 48

Teamsters Flex Muscle in Bakery Dispute Sometimes, it's a matter of holding your ground until the last minute. That’s exactly the brand of guts the workers at Bimbo Bakeries in Chicago just displayed, securing a robust agreement mere hours before hitting the picket line. These 275 warehouse and route sales folks threw down the gauntlet with management and,...

Continue Reading
Medline's MedTrans Rodeo: Honoring Driver Excellence

Updated Category News Views 52

Rollin' Down the Road of Excellence In the world of healthcare logistics, Medline's MedTrans team isn't just steering trucks—they're steering safety culture and supply chain efficiency. This October, they wrapped up their fourth annual National Truck Rodeo in Mundelein, Illinois. And let me tell you, it was more than just a fancy event. It was about celebrating the real...

Continue Reading
Concrete Admixtures Market: A Billion-Dollar Boom

Updated Category News Views 24

A Look Under the Hood of Concrete Admixtures It's a concrete jungle out there, folks—literally. The once overlooked market of concrete admixtures is gearing up for quite the makeover, projected to hit USD 35.87 billion by 2035. For those of you tuning in, we're talking about chemicals that mix into your average concrete to change its properties. And, believe it or not,...

Continue Reading
Dimora Medical Boosts Advanced Wound Care at HS Conference

Updated Category News Views 74

Empowering the HS Community with Innovations Look, if you’ve walked a mile in someone else's shoes—particularly ones dealing with hidradenitis suppurativa (HS)—you’d know what a relentless grind managing those exuding wounds can be. Dimora Medical, known for navigating the tricky territory of wound care, threw its hat into the ring at the HS Connect Empower...

Continue Reading
Bay Area to Host New Jerry Garcia Arts Center

Updated Category News Views 43

Celebrating a Legend in the Heart of San Francisco The Bay Area is set to become home to a vibrant new center dedicated to celebrating the multifaceted legacy of Jerry Garcia, Grateful Dead co-founder. Announced by the Garcia family, with the help of archival platform Starchive and project coordinator Christopher McCutcheon, the Jerry Garcia Music Arts Center promises to...

Continue Reading

Top 5 Most Recently Viewed Articles

Legal Investigation: Crocs Investors Urged to Act Now

Updated Category News Views 109

Investors Encouraged to Take Action Regarding Crocs Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson encourages investors who suffered losses exceeding $100,000 in Crocs to contact him directly to discuss their options. If you have experienced losses of over $100,000 related to Crocs during recent financial periods, calling Faruqi & Faruqi might...

Continue Reading
Exploring the Impact of .lunar Domains on Space Ventures

Updated Category News Views 120

Unveiling the .lunar Domain Extension Unstoppable Domains and Copernic Space have made waves with their groundbreaking initiative involving the launch of the .lunar domain extension. This innovative top-level domain is designed specifically for trailblazers exploring the realms of space, cryptocurrencies, and decentralized physical infrastructure networks (DePIN). By...

Continue Reading
Investigation Launched for Investors in Dave Inc. - DAVE

Updated Category News Views 297

Investigation Overview for Dave Inc. Investors Pomerantz LLP is currently conducting an investigation aimed at protecting the interests of investors in Dave Inc. (NASDAQ: DAVE). Investors concerned about the validity of their investments or those seeking to understand more about potential corporate misconduct are encouraged to reach out. Key Allegations Against Dave Inc....

Continue Reading
Innovative Solutions Unveiled at Safety Pharmacology Society Meeting

Updated Category News Views 51

Exciting Innovations from Harvard Bioscience Harvard Bioscience, Inc. (NASDAQ: HBIO) is gearing up to present a variety of groundbreaking products at an important annual gathering tailored for safety pharmacologists. The company is dedicated to advancing life sciences and has crafted solutions that meet the varied needs of researchers and developers in the pharmaceutical...

Continue Reading
Upcoming Earnings Report for Cinemark Holdings Inc.

Updated Category News Views 138

Key Insights Ahead of Cinemark's Earnings Release Cinemark Hldgs (CNK) is gearing up to unveil their quarterly earnings report. Investors are buzzing with anticipation, keen to see how the company measures up against analyst expectations. Analysts are predicting an earnings per share (EPS) of $0.76, a number that reflects optimistic sentiment surrounding the company's...

Continue Reading